COPS5 and diffuse large B-cell lymphoma: In particular, we identified COPS5 as a novel biomarker for diffuse large B-cell lymphoma (DLBCL) and experimentally validated by the CRISPR-Cas9 knockout, which supports the feasibility of our approach.